🔎 Trials Near Me

Home › Linfoma non Hodgkin › Ohio

Studi clinici su Linfoma non Hodgkin nello stato di Ohio

34 studi su Linfoma non Hodgkin cercano partecipanti presso sedi nello stato di Ohio.

Città nello stato di Ohio

Testo ufficiale dello studio (inglese)

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  • Study Site 104, Columbus
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07582432

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • University Hospitals Seidman Cancer Center, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06343311

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 105, Canton
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT05645107

Epco, Zanu, Ritux for R/R FL or MZL

  • The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06563596

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • The Ohio State University (OSU), Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07101328

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • University of Cincinnati Medical Center, Cincinnati
  • Kettering Health, Kettering
  • West Chester Hospital, West Chester
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06526793

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07225439

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

  • Clinical Trial Site, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06393738

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
  • Cleveland Clinic, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT05826535

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 1/2
12 Months – 30 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04851119

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Cincinnatti Medical Center, Cincinnatti
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06528301

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Oncology Hematology Care Clinical Trials, Cincinnati
  • University of Cincinnati, Cincinnati
  • Cleveland Clinical Taussig Cancer Center, Cleveland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • The Ohio State University Wexner Medical Center James Cancer, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT04792489

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

  • The Ohio state University, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 lug 2026 · NCT05077527

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Childrens Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital, Cincinnati
  • University Hospitals Case Medical Center, Cleveland
  • e altri 3
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
In reclutamentoFase 1
Età da 18 a 65 · Tutti i sessi · Aggiornato il 25 giu 2026 · NCT06447376

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 2 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
In reclutamentoFase 1
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

  • The Ohio State University, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 apr 2026 · NCT06801002

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Cleveland Clinic, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 apr 2026 · NCT03328078

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Indu and Raj Soin Medical Center, Beavercreek
  • Strecker Cancer Center-Belpre, Belpre
  • Dayton Physician LLC - Englewood, Dayton
  • e altri 9
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Gabrail Cancer & Research Center, Canton
  • The Ohio State University - The James Cancer Hospital, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Taylor Cancer Research Center, Maumee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Cincinnati
  • Massive Bio SYNERGY-AI site, Columbus
  • Massive Bio SYNERGY-AI site, Mayfield Heights
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University Hospitals Cleveland Medical Center, Cleveland
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2025 · NCT05780034

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • University Hospitals Cleveland, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2025 · NCT06119685

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

  • University Hospitals Seidman Cancer Center, Cleveland
  • Taussig Cancer Institute | Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ott 2024 · NCT05312801

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

  • University of Cincinnati, Cincinnati
  • The Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2022 · NCT04502394

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.